LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
26 funds hold it · Insiders net selling
Net selling: insiders sold $29.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 3, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.68 expected
Estimates as of Nov 9, 2026
EPS expected
$1.01 to $1.31
Revenue expected
4 analysts
Last 30 days
Analysts cutting estimates
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 3, 2026 | $1.01est. $0.68 | +48.53%beat | $340.5MSEC filing | +64.0%from $207.6M |
| Jun 30, 2026Reported Jul 29, 2026 | $0.36est. -$0.04 | +$0.40beat | $256.1MSEC filing | +31.7%from $194.4M |
| Mar 31, 2026Reported Apr 30, 2026 | -$0.30est. -$0.14 | -114.29%miss | $164.9MSEC filing | +4.9%from $157.2M |
| Dec 31, 2025Reported Feb 24, 2026 | $0.20est. $0.25 | -21.26%miss | $202.1MAlpha Vantage | +11.1%from $181.9M |
| Sep 30, 2025Reported Nov 4, 2025 | $0.16est. $0.14 | +14.29%beat | $207.6MSEC filing | +13.7%from $182.5M |
| Jun 30, 2025Reported Jul 31, 2025 | $0.29est. $0.19 | +52.63%beat | $194.4MSEC filing | +18.7%from $163.8M |
| Mar 31, 2025Reported May 5, 2025 | $0.17est. $0.14 | +21.43%beat | $157.2MSEC filing | +7.1%from $146.8M |
| Dec 31, 2024Reported Feb 26, 2025 | Not on file | No estimate | $181.9MAlpha Vantage | +34.3%from $135.4M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $202.1M | $164.9M | $256.1M | $340.5M |
| Cost of what it sold | $2.5M | $2.9M | $4.1M | $4.6M |
| Gross profit | $199.6M | $162.0M | $252.1M | $335.9M |
| What it spent | ||||
| Research and development | $64.9M | $66.3M | $53.9M | $56.7M |
| Sales and admin | $130.2M | $145.4M | $156.9M | $164.4M |
| Total operating expenses | $195.1M | $211.6M | $210.8M | $221.1M |
| What was left | ||||
| Operating profit | $4.5M | -$49.6M | $41.3M | $114.7M |
| Profit before tax | $9.9M | -$44.7M | $45.9M | $120.3M |
| Tax | -$14.4M | -$13.5M | -$2.9M | -$6.5M |
| Net profit | $24.3M | -$31.2M | $42.1M | $126.8M |
| EBITDA | $10.4M | -$44.1M | $46.8M | $121.3M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Form 144 CORCEPT THERAPEUTICS INCORPORATED For: 11 November By Investing.com
NeutralNov 11A director proposes selling 1,500 shares of Corcept Therapeutics (CORT).
NeutralNov 10Can You Justify Buying Corcept Stock Today?
NeutralNov 6Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build
Leans bullishNov 6Corcept Therapeutics (CORT) Stock Trades At A Premium On Strong Q3 Earnings
Leans bearishNov 5Corcept president of oncology Vieira sells $674,068 in stock
Leans bearishNov 525,000 Corcept Therapeutics (CORT) shares sold under Sean Maduck’s prearranged trading plan.
NeutralNov 5Corcept Therapeutics former president Sean Maduck sells $2.05M in stock
Leans bearishNov 4
